LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
RLYB
Rallybio Corporation
There isn't enough reported data to score RLYB yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
RLYB Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Stable | |
| Strong | |
| Unavailable |
RLYB's cash flow is currently strong, and its profitability is stable, but its revenue is weak. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
RLYB PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 2.1x | $9.58 | -39% |
| Fair | 2.1x | $9.76 | -38% |
| Expensive | 2.9x | $13.40 | -14% |
| Current | 3.4x | $15.65 | — |
Historical ranges are pointers, not guarantees.
RLYB has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
RLYB Forward outlook
There aren't enough analyst estimates for RLYB to show an outlook.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
RLYB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $4.56 | +$6.96 |
| Q2 2026 | $7.92 | +$15.28 |
| Q1 2026 | -$1.37 | +$7.19 |
| Q4 2025 | -$1.59 | +$9.05 |
| Q3 2025 | -$2.40 | +$10.40 |
| Q2 2025 | -$7.36 | +$6.96 |
| Q1 2025 | -$8.56 | +$6.48 |
| Q4 2024 | -$10.64 | +$4.08 |
RLYB has returned to profit: it earned $4.56 per share over the past year, after losing money the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over RLYB on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
RLYB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $212K | 0% |
| Q4 2025 | $222K | +11000% |
| Q3 2025 | $212K | -29% |
| Q2 2025 | $212K | -29% |
RLYB's revenue has slid since its 2024 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -4119% | +442 points |
| Q4 2025 | -2888% | +577512 points |
| Q3 2025 | -3267% | +769 points |
| Q2 2025 | -4744% | +953 points |
| Q1 2025 | -4561% | N/A |
| Q4 2024 | -580400% | N/A |
| Q3 2024 | -4035% | N/A |
| Q2 2024 | -5697% | N/A |
RLYB's operating margin was −4119% last quarter, up 442 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
RLYB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.3M | +$4.3M |
| Q2 2026 | $45.9M | +$54.3M |
| Q1 2026 | -$8M | +$2.2M |
| Q3 2025 | -$6.6M | +$7M |
| Q2 2025 | -$8.4M | +$2M |
| Q1 2025 | -$10.2M | +$5.3M |
| Q3 2024 | -$13.5M | +$2.9M |
| Q2 2024 | -$10.4M | +$3M |
RLYB has the edge over LLY on cash flow, with more consistent year-over-year improvement.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over RLYB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
RLYB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.4% | -82.9K shares |
| 1 year | +1.5% | +82.7K shares |
| 3 years | +13% | +649K shares |
| 5 years | +1049% | +5.2M shares |
| Available history | +106% | +2.9M shares |
RLYB has 6M diluted shares, up 1.5% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
RLYB Net Leverage
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
RLYB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.4 | Neutral |
| Stochastic | 17.7 | Oversold |
RLYB's weekly RSI is 54 (neutral) and its Stochastic is 18 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
RLYB PE vs Healthcare Sector
| Metric | RLYB | Sector median | Relative |
|---|---|---|---|
| PE | 3.4x | 26x | 87% below |
RLYB has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over RLYB on trend strength, trading above more of its moving averages.
RLYB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $16.3 | 4.1% below |
| 20 week MA | $16.4 | 4.7% below |
| 50 week MA | $12.1 | 29% above |
| 100 week MA | $8.34 | 88% above |
| 200 week MA | $17.4 | 10% below |
RLYB's trend is mixed: it's above two of its five weekly moving averages, and 10% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
RLYB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $136.0 | $91.6 | -33% |
| 2022 | $91.6 | $46.0 | -50% |
| 2023 | $46.0 | $19.1 | -58% |
| 2024 | $19.1 | $7.31 | -62% |
| 2025 | $7.31 | $5.50 | -25% |
| 2026 YTD | $5.50 | $15.7 | +185% |
RLYB has the edge over LLY on returns for 2026, with the stronger performance.